文献速递烧伤

大面积烧伤高热:流行病学描述与血管内控温装置效果评估

Hyperpyrexia in major burn injury: describing the epidemiology and evaluating the effectiveness of an intravascular temperature management device.
PubMed 文献 · Burns · 2026-06-15

56例患者中30例(56.3%)出现高热,高热与火焰烧伤、更大TBSA和更长住院时间相关,但死亡率无显著差异;8例使用Thermogard XP®者似乎比标准干预更快达到常温。

要点

  • 大面积烧伤患者高热发生率较高,本队列为56.3%。
  • 高热与火焰烧伤、更大烧伤面积和更长住院时间相关,但未增加死亡率。
  • Thermogard XP®可能更快控制≥39.5°C高热,但证据来自小样本单中心观察。

核心结论

  • 高热与更严重的烧伤损伤和更高的干预需求相关,但未增加死亡率。
  • Thermogard XP®在该小样本单中心观察性研究中似乎能有效控制≥39.5°C的高热。
  • 未来仍需进一步研究其有效性及对生存等结局的影响。

研究设计与样本

  • 使用中心数据库和电子病历收集人口学、烧伤严重程度、干预和结局数据,并记录高热发作和Thermogard XP®使用情况。
  • 采用多水平中断时间序列分析,比较Thermogard XP®与历史对照在降低体温方面的效果。

主要发现

  • 共分析56例患者,其中30例(56.3%)出现高热(≥39.5°C)。
  • 高热队列更可能为火焰烧伤(p=0.003)、烧伤TBSA更大(p=0.006)、住院时间更长(p=0.005)。
  • 高热患者与非高热患者死亡率无显著差异。
  • 8例患者使用Thermogard XP®,似乎比标准干预更快达到常温。

关键数值与推荐

  • 高热定义为体温≥39.5°C。
  • 纳入标准为成年、TBSA≥20%的大面积烧伤。
  • 高热队列火焰烧伤p=0.003,烧伤TBSA p=0.006,住院时间p=0.005。

临床怎么用

  • 对TBSA≥20%的烧伤患者应警惕高热,尤其火焰烧伤和更大面积烧伤者。
  • 高热提示需要更多干预,但不必据此判断死亡率升高。
  • Thermogard XP®可作为控制≥39.5°C高热的可选手段,但需结合本单位条件和证据谨慎使用。

局限性

  • 单中心、小样本(56例)回顾性观察性研究。
  • 使用Thermogard XP®的患者仅8例,证据有限。
  • 作者指出未来仍需进一步研究其有效性及对生存等结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Hyperpyrexia is a complication of burn injury, likely caused by systemic inflammation and infection, the pathophysiology of which is poorly understood. This study aimed to describe the patient cohort who developed hyperpyrexia (≥39.5°C) and evaluate the effectiveness of the Thermogard XP Icy®, an intravascular temperature management device, in restoring normothermia. METHODS: This was a retrospective cohort study of adult patients admitted to Glasgow Royal Infirmary's intensive care unit with major burns (TBSA ≥20%) between January 2016 and October 2024. A central database and electronic medical records were used to collect data on demographics, burn severity, interventions and outcomes. Episodes of hyperpyrexia and Thermogard XP® use were also recorded. A multilevel interrupted time series analysis was used to assess the effectiveness of the Thermogard XP® device in reducing body temperature in comparison to historic controls. RESULTS: Fifty-six patients were analysed, of which 30 (56.3%) developed hyperpyrexia. This cohort were more likely to have sustained a flame burn (p = 0.003), have a greater burn TBSA (p = 0.006) and longer hospital stay (p = 0.005) when compared to non-hyperpyrexic patients; however, mortality rates did not differ significantly. Eight patients were managed with a Thermogard XP®; this appeared to achieve normothermia quicker than standard interventions. CONCLUSION: Hyperpyrexia was associated with more severe burn injuries and greater intervention requirements but not increased mortality. The Thermogard XP® seemed effective at controlling temperatures ≥ 39.5°C in this small single-centre observational study; future studies are needed to further explore its effectiveness and impact on outcomes such as survival.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. McGovern C, Morris H, Paton L, et al. Hyperpyrexia in major burn injury: describing the epidemiology and evaluating the effectiveness of an intravascular temperature management device. Burns. 2026. PMID: 42379066. doi:10.1016/j.burns.2026.108113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。